Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Checkpoint Therapeutics ( (CKPT) ) has provided an announcement.
Checkpoint Therapeutics, Inc. announced the completion of a merger on May 30, 2025, with Snoopy Merger Sub, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries, Inc. As part of the merger, all shares of Checkpoint Therapeutics were converted into cash and contingent value rights, with trading on Nasdaq suspended and delisting initiated. The merger resulted in changes to the company’s leadership and corporate structure, impacting its market presence and shareholder value.
The most recent analyst rating on (CKPT) stock is a Hold with a $4.10 price target. To see the full list of analyst forecasts on Checkpoint Therapeutics stock, see the CKPT Stock Forecast page.
Spark’s Take on CKPT Stock
According to Spark, TipRanks’ AI Analyst, CKPT is a Neutral.
Checkpoint Therapeutics faces significant financial challenges with declining revenues and negative margins. However, the technical analysis shows strong upward momentum, and the recent merger agreement with Sun Pharma provides a positive outlook. The valuation remains unattractive due to the negative P/E ratio. Overall, while there are short-term opportunities, substantial financial issues pose long-term risks.
To see Spark’s full report on CKPT stock, click here.
More about Checkpoint Therapeutics
Average Trading Volume: 3,127,299
Technical Sentiment Signal: Buy
Current Market Cap: $370.7M
For a thorough assessment of CKPT stock, go to TipRanks’ Stock Analysis page.